Myriad Genetics, Inc. develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers.
Market Cap | 1.617 Billion | Shares Outstanding | 81.034 Million | Avg 30-day Volume | 564.046 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.2 |
Price to Revenue | 2.328 | Debt to Equity | 0.0 | EBITDA | -78.6 Million |
Price to Book Value | 1.6799 | Operating Margin | -19.8821 | Enterprise Value | 1.281 Billion |
Current Ratio | 2.729 | EPS Growth | 0.541 | Quick Ratio | 2.288 |
1 Yr BETA | 1.4661 | 52-week High/Low | 28.18 / 13.92 | Profit Margin | -11.6873 |
Operating Cash Flow Growth | -207.1076 | Altman Z-Score | 3.1636 | Free Cash Flow to Firm | -194.55 Million |
Earnings Report | 2023-02-23 |
Please sign in first
none
30 Thousand total shares from 3 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
RIGGSBEE RICHARD BRYAN CHIEF FINANCIAL OFFICER |
|
364,107 | 2023-01-20 | 9 |
LAMBERT NICOLE CHIEF OPERATING OFFICER |
|
228,404 | 2023-01-01 | 7 |
MUZZEY DALE CHIEF SCIENTIFIC OFFICER |
|
42,712 | 2023-01-01 | 5 |
|
0 | 2022-10-31 | 2 | |
WONG PAMELA CHIEF LEGAL OFFICER |
|
51,860 | 2022-10-18 | 3 |
VERRATTI MARK CHIEF COMMERCIAL OFFICER |
|
228,022 | 2022-10-09 | 8 |
HART JAYNE B. CHIEF PEOPLE OFFICER |
|
172,561 | 2022-10-09 | 8 |
HAAS KEVIN RICHARD CHIEF TECHNOLOGY OFFICER |
|
85,295 | 2022-10-09 | 6 |
MUNK NATALIE CHIEF ACCOUNTING OFFICER |
|
25,186 | 2022-08-25 | 2 |
DIAZ PAUL J PRESIDENT AND CEO |
|
1,087,079 | 2022-08-13 | 4 |
|
136,802 | 2022-06-30 | 2 | |
|
33,980 | 2022-06-06 | 2 | |
|
100,802 | 2022-06-02 | 1 | |
|
129,921 | 2022-06-02 | 1 | |
|
57,699 | 2022-06-02 | 1 | |
|
55,164 | 2022-06-02 | 1 | |
|
57,699 | 2022-06-02 | 1 | |
|
54,046 | 2022-06-02 | 1 | |
SANTA ERIC FORMER CHIEF GROWTH OFFICER |
|
56,734 | 2022-04-26 | 4 |
ANCONA MARGARET SEE REMARKS |
|
37,160 | 2022-03-22 | 2 |
LANCHBURY JERRY S SEE REMARKS |
|
264,324 | 2022-01-14 | 0 |
|
83,527 | 2021-06-03 | 0 | |
PARKINSON PAUL FMR EVP STRATEGY & INNOVATION |
|
No longer subject to file | 2021-05-14 | 0 |
JACKSON BENJAMIN FORMER E.V.P., GENERAL COUNSEL |
|
No longer subject to file | 2021-04-12 | 0 |
FORD ALEXANDER CHIEF OPERATING OFFICER |
|
169,040 | 2020-09-30 | 0 |
|
54,150 | 2019-12-13 | 0 | |
|
60,790 | 2019-12-05 | 0 | |
|
78,090 | 2019-12-05 | 0 | |
CAPONE MARK CHRISTOPHER PRESIDENT & C.E.O. |
|
522,216 | 2019-09-30 | 0 |
KING GARY A. EXEC. VP INTERNATIONAL OPS |
|
148,397 | 2019-09-30 | 0 |
MCDADE RALPH L PRESIDENT MYRIAD RBM, INC. |
|
142,095 | 2019-09-30 | 0 |
TOBIN BERNARD PRESIDENT CRESCENDO BIOSCIENCE |
|
160,636 | 2019-09-30 | 0 |
MARSH RICHARD M E.V.P., GENERAL COUNSEL |
|
144,174 | 2018-09-30 | 0 |
SANDERS WALTER LLOYD PRESIDENT MYRIAD ONCOLOGY |
|
36,195 | 2018-09-30 | 0 |
WENSTRUP RICHARD CHIEF MEDICAL OFFICER |
|
50,207 | 2016-09-30 | 0 |
DROSOS VIRGINIA PRESIDENT ASSUREX HEALTH |
|
50,000 | 2016-09-14 | 0 |
MELDRUM PETER D PRESIDENT & C.E.O. |
|
10,869 | 2014-11-05 | 0 |
EVANS JAMES S CHIEF FINANCIAL OFFICER |
|
48,128 | 2014-09-30 | 0 |
HARRISON ROBERT GARDNER CHIEF INFORMATION OFFICER |
|
25,844 | 2014-09-17 | 0 |
ROGERS RONALD S. EXEC VP CORP COMMUNICATIONS |
|
16,000 | 2014-09-17 | 0 |
HAGSTROM WILLIAM A PRES. CRESCENDO BIOSCIENCE |
|
0 | 2014-02-28 | 0 |
BENSON T CRAIG PRESIDENT, MYRIAD RBM |
|
0 | 2013-09-17 | 0 |
|
2,500 | 2010-01-07 | 0 | |
SKOLNICK MARK H CHIEF SCIENTIFIC OFFICER |
|
549,001 | 2009-11-04 | 0 |
|
0 | 2009-11-04 | 0 | |
CRITCHFIELD GREGORY C PRESIDENT MYRIAD GENETIC LABS |
|
0 | 2009-09-15 | 0 |
HOBDEN ADRIAN N PRES. MYRIAD PHARMACEUTICALS |
|
234,071 | 2009-06-08 | 0 |
LASLIE W WAYNE CHIEF OPERATING OFFICER, MPI |
|
44,260 | 2009-05-08 | 0 |
|
0 | 2008-11-13 | 0 | |
HOCKETT WILLIAM A III V. P. OF CORP COMMUNICATIONS |
|
0 | 2008-09-10 | 0 |
HAYES ARTHUR HULL JR |
|
15,000 | 2007-11-15 | 0 |
MOYES JAY M CHIEF FINANCIAL OFFICER |
|
25,282 | 2007-10-15 | 0 |
SIMON S GEORGE V.P. BUSINESS DEVELOPMENT |
|
21,410 | 2007-01-16 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-23 16:14:05 -0500 | 2023-01-20 | S | 9,400 | $20.04 | d | 364,107 | direct | yes | -2.1936 | -5.9609 | 0.0 | 1 | -8.1545 | 5 | ||
2023-01-19 17:56:22 -0500 | 2023-01-18 | S | 600 | $20.01 | d | 373,507 | direct | yes | 5.2088 | 0.0983 | 5.2088 | 2 | -2.6536 | 5 | ||
2023-01-04 18:07:19 -0500 | 2023-01-01 | F | 853 | $14.51 | d | 228,404 | direct | 2.2458 | 17.1553 | 17.1553 | 6 | 0.0 | 1 | |||
2023-01-04 18:09:17 -0500 | 2023-01-01 | F | 302 | $14.51 | d | 42,712 | direct | 2.2458 | 17.1553 | 17.1553 | 6 | 0.0 | 1 | |||
2022-12-28 16:05:33 -0500 | 2022-12-27 | S | 20,000 | $15.15 | d | 374,107 | direct | yes | -0.6164 | 12.2603 | 12.2603 | 6 | -0.6164 | 2 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
MYRIAD GENETICS INC MYGN | 2023-02-03 22:15:03 UTC | 4.32 | 0.25 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 21:45:03 UTC | 4.32 | 0.25 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 21:15:03 UTC | 4.32 | 0.25 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 20:45:06 UTC | 4.32 | 0.25 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 20:15:04 UTC | 4.32 | 0.25 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 19:45:03 UTC | 4.32 | 0.25 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 19:15:04 UTC | 4.32 | 0.25 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 18:45:03 UTC | 4.2992 | 0.2708 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 18:15:03 UTC | 4.2992 | 0.2708 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 17:45:03 UTC | 4.2992 | 0.2708 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 17:15:04 UTC | 4.2992 | 0.2708 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 16:45:04 UTC | 4.1619 | 0.4081 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 16:15:03 UTC | 4.1619 | 0.4081 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 15:45:03 UTC | 4.1619 | 0.4081 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 15:15:03 UTC | 4.1619 | 0.4081 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 14:45:04 UTC | 3.9119 | 0.4081 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 14:15:04 UTC | 3.9119 | 0.4081 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 13:45:03 UTC | 3.9119 | 0.4081 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 13:15:03 UTC | 3.9119 | 0.4081 | 3500000 |
MYRIAD GENETICS INC MYGN | 2023-02-03 12:45:03 UTC | 3.9119 | 0.4081 | 3100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Enhanced Index Plus Fund | MYGN | -561.0 shares, $-8027.91 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | MYGN | -311.0 shares, $-4450.41 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | MYGN | -526.0 shares, $-7527.06 | 2020-03-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | MYGN | -5200.0 shares, $-99216.0 | 2022-09-30 | N-PORT |
Columbia Funds Series Trust I- Multi-Manager Directional Alternative Strategies Fund | MYGN | -6474.0 shares, $-134270.76 | 2022-10-31 | N-PORT |